Clinical Trials
2 trialsNCT05237947 2026-05-28
PRISMA
National Cancer Institute (NCI)
Phase 4 Active not recruiting
NCT02518555 2026-04-06
Ibrutinib as an Immune Modulating Agent for Patients With Asymptomatic, High-risk CLL/SLL Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Ohio State University Comprehensive Cancer Center
Phase 2 Completed